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Introduction
The scientific literature on probiotics commences with the Russian 
Nobel laureate, Elie Metchnikoff, who suggested that ingestion of 
lactic acid-producing bacteria, such as that found in yoghurt, was 
a protective factor, enhancing longevity and potentially beneficial 
in treating digestive diseases.1 Probiotic research is a relatively 
young, but rapidly expanding field. By mid-2010, there were 
7 180 publications in the PubMed database, of which 26% (1 863) 
were reviews. By comparison, the search term “antibiotics” yielded 
509 728 publications, of which 8.5% (43 515) were reviews. 
Therefore, it can be concluded that the field of probiotics does not 
suffer from too few reviews, but rather from insufficient original 
research.2 
The term “probiotic” is derived from the Latin “pro” (meaning for) 
and the Greek “bios” (meaning life). The World Health Organization 
(WHO) and the Food and Agricultural Organization (FAO) of the United 
Nations have defined probiotics as “live microorganisms, that when 
administered in adequate amounts, have beneficial effects for the 
host.”3 Some definitions have also changed the word “administered” 
to “consumed.”4 Although this is the acknowledged scientific 
definition, there is no legal definition for the term “probiotic”. 
Unfortunately, the definition is often used by industry, even when the 
minimum scientific criteria for probiotics are not met.5
Colonisation and diversity of gut microbiota
The gut microbiota comprises a complex ecological system, 
consisting of at least 500 different bacterial species, yeasts, 
protozoa, viruses and fungi, and this microbiota plays an integral 
part in the digestive and metabolic processes that are essential for 
general well-being.6 The bacterial microbiota is the most reported 
and researched.7 Inherent colonisation of microbiota occurs 
at birth with organisms that inhabit the skin, oral cavity, vagina 
and gastrointestinal tract.8 This colonisation is influenced by the 
route of delivery (vaginal vs. Caesarean section), gestational age 
(prematurity vs. full term), and use of antibiotics in the perinatal 
period, especially in the neonatal intensive care unit setting. For 
example, vaginal births are associated with a greater intestinal 
colonisation by bifidobacteria, but not lactobacilli, compared to 
Caesarean section deliveries.9 In comparison, Caesarean section 
births are associated with increased colonisation by Klebsiella, 
Enterobacter and Clostridium. These organisms are common in 
hospital settings.10 Early feeding practices also influence microbial 
colonisation. Breastfed infants have less intestinal permeability, 
compared to formula-fed infants.11 Formula feeding is associated 
with an increased presence of both Clostridium and Bacteroides 
in the intestinal tract.10 Poor microbial variety in infancy seems to 
be related to a greater risk of atopic disease later in childhood.12 
The initial acquisition of intestinal microbiota plays a key role in 
the development of immune processes and protection against 
pathogens. A reduction in the variety of the gut microbiome often 
occurs in a number of conditions that are potentially related to 
dysbiosis, including inflammatory bowel disease and chronic 
diarrhoea.13
Dysbiosis
Disturbances in the sensitive balance between the host and the 
intestinal microbiota (dysbiosis) can lead to changes in the mucosal 
immune system that range from obvious inflammation, as seen in 
Crohn’s disease, to low-grade inflammation, evidenced in a subset 
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of irritable bowel syndrome (IBS) patients.14 Research verifies 
the significance of the colonising microbiota in determining the 
equilibrium of proinflammatory to regulatory cells in the gut.15,16 
Variations in the intestinal microbiota balance have been associated 
with obesity,17,18 Crohn’s disease, ulcerative colitis and coeliac 
disease.19-21 These conditions have been linked to less species 
variation and abnormal immune responses to intestinal bacteria.
The faecal microbiota of IBS patients differs significantly from 
that of healthy subjects.22 Balsari studied stool samples of 20 
IBS patients and noted a decrease in coliforms, lactobacilli and 
bifidobacteria, compared to that in healthy individuals.23 Similar 
results have been found in other studies.24,25 A further study that 
divided IBS patients according to subtype, showed that diarrhoea-
predominant IBS (D-IBS) patients had lower numbers of lactobacilli, 
while constipation-predominant IBS (C-IBS) patients had increased 
numbers of Veillonella spp.26 Despite the fact that dysbiosis has 
progressively become better documented in various intestinal 
diseases,27,28 it remains to be seen whether this is, in fact, a cause-
and-effect relationship.
Probiotic organisms
In the stomach, small numbers of probiotic organisms [0-103 
colony-forming units (CFU) per gram] are found, consisting mainly 
of lactobacilli, streptococci, staphylococci, enterobacteriacae and 
yeasts. These small numbers are primarily because of the low 
intragastric pH. Subsequently, there is an increase from 0-105 CFU 
per g in the duodenum, to 108 CFU per gram in the ileum, and 1010-
1012 CFU per gram in the colon because of the neutral intestinal 
pH, a slower transit time and the availability of nutrients. In the 
colon, > 99% of the microorganisms are strictly anaerobic, such as 
bifidobacteria, Bacteroides spp., Clostridium spp., Eubacterium spp., 
Fusobacterium spp. and peptostreptococci.6,29 As part of the normal 
microflora, Lactobacillus and Bifidobacterium genera vary from 106-
1010 in different individuals. For probiotic bacteria to be effective, 
they need to transit through the gastrointestinal tract that contains 
gastric juices, bile and pancreatic juice. Adhesion to the intestinal 
mucosa is considered to be a prerequisite for interaction with the 
immune system.30
Nomenclature of probiotics
Probiotics need to be classified according to their genus 
(e.g. Lactobacillus), species (e.g. rhamnosus) and strain (e.g. GG). 
This level of specificity in describing a probiotic is important, as 
effects can be and are, strain-specific. For example, L. plantarum 
299v may have a different mechanism of action and effect to L. 
plantarum MF1298. It is important to look for probiotics that are 
supported by strain-specific research.4,5
Clinical application of probiotics
Probiotic usage is likely to attract the interest of two groups of people: 
healthy people who are interested in probiotics to keep them that 
way, and people with specific health concerns, about which evidence 
of probiotic efficacy is available. The second group is motivated 
and has a measurable outcome: symptom improvement.5 Several 
functions of the gut microbiota may be influenced by probiotics 
beneficially. Probiotics have been studied in a number of diseases, 
especially when intestinal bacteria are thought to be involved in their 
pathogenesis.2 The main study areas and application of probiotics 
are a direct result of their mechanisms of action. The clinical benefits 
of probiotic usage include those related to improvement of the gut 
epithelial or mucosal layer, strengthening of the immune response, 
and prevention of diseases later in life, e.g. eczema, atopic eczema, 
allergic rhinitis and cancer. The consensus recommendations for 
the correct clinical use of probiotics in various scenarios, as well 
as examples of probiotic strains and their associated published 
benefits, are tabulated in Table I.
Table I: Examples of probiotic strains and their associated published benefits5,31
Indication Genus, species, strain
Infant diarrhoea Lactobacillus rhamnosus GG
L. casei DN-114001
L. reuteri 
Inflammatory bowel conditions  
(primary evidence in pouchitis)
Multistrain probiotic containing 
three Bifidobacterium strains, four 
lactobacillus strains, and 
Streptococcus thermophilus (VSL#3) 






L. acidophilus CL1285 plus L. casei
L. bulgaricus
Gut transit time Bifidobacterium animalis DN-173 010
Keeping healthy L. reuteri ATCC 55730
L. casei DN-114001
Atopic dermatitis L. rhamnosus GG
B. lactis
Lactose intolerance Most strains 
L. bulgaricus and/or S. thermophilus
Colic in infants L. reuteri ATCC 55730








Vaginal applications L. rhamnosus GR1 plus L. reuteri 
RC14
L. acidophilus
Irritable bowel syndrome L. plantarum 299v
B. infantis 35264
Mechanism of action
The microbiota performs many significant functions for the host. 
These include the production of vitamins, degradation of bile 
acids, conversion of (pro)carcinogenic substances and digestion 
of nutrients.30 Anaerobic bacteria are of benefit to the host by 
performing metabolic functions, such as fermentation, providing 
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short-chain fatty acids (SCFAs), producing vitamins, adding to the 
trophic action of the epithelium, and aiding in the development of 
the immune system.32 Saccharolytic fermentation of unabsorbed 
and indigestible carbohydrates by intestinal bacteria occurs mainly 
in the colon. This is essential, as SCFAs (i.e. acetate, propionate 
and butyrate) are produced.33 Butyrate, a major energy source for 
intestinal epithelial cells, affects cell proliferation and differentiation, 
increases mucus secretion and decreases inflammation.34 Proteolytic 
bacterial fermentation usually takes place in the more distal colon, 
where carbohydrates are no longer available, and results in the 
production of toxic compounds like ammonia, phenols, cresols and 
paracresols.35
The exact mechanism by which probiotics exert their favourable 
effect has not been fully elucidated. Different strains of organisms 
have very diverse and specialised metabolic activity. Proposed 
mechanisms include those responsible for the manipulation and 
regulation of the intestinal microbial balance, those that protect the 
mucosa against pathogenic invasion (adhesion and translocation), 
and those that modulate an appropriate immune response.36,37 
In the gastrointestinal tract, probiotics can aid with the following: 
• The secretion of antibacterial substances, e.g. bacteriocins 
and acids, which result in a reduction in the luminal pH, with 
decreased growth ability of the pathogens.
• The production of intestinal mucin, which influences bacterial 
colonisation, and human β-defensins (peptides with antibacterial 
properties), which affect mucosal adherence, and inhibit 
pathogenic bacteria adherence.
• The expression of receptors (toll-like receptors 2 and 4), that 
sense bacterial components and trigger an appropriate immune 
response through the release of protective cytokines (IL-6).
• An increased release of secretary IgA that can protect the 
microflora against bacterial attachment.
• The regulation of epithelial cell apoptosis.
• The acidification of the colon by nutrient fermentation.36-39
The immune response is modulated by controlling levels of circulating 
inflammatory cytokines (NF-κB and TGF-β), restoring the imbalance 
between Th1 and Th2 responses, and increasing the expression of 
heat-shock proteins which are essential for the maintenance of the 
epithelial barrier function. Through an appropriate pro- and anti-
inflammatory response, the immune function is regulated suitably for 
each condition in a strain-specific manner.36,37,39,40 Certain probiotic 
strains also exhibit anticarcinogenic effects by increasing faecal 
mutagen excretion, and inhibiting the conversion of precarcinogens 
to carcinogens by reducing the enzyme β-glucuronidase.39 Indirectly, 
this anticarcinogenic effect is seen by an increased immune 
response (as discussed previously).
Dose
Dose levels of probiotics should be based on levels that are found 
to be efficacious in human studies.41 The necessary amount and 
duration of use depends on the specific strain and the health 
condition being studied. Studies demonstrating beneficial results 
at levels < 100 million (108) CFU/day are uncommon in published 
literature. For example, the efficacy of Bifidobacterium infantis 35264 
has been documented at 108 CFU/day,42 whereas the recommended 
dose of VSL#3 is 1.8 x 1012CFU/day (a four-log-cycle difference).43 
This disparity underlines the inaccuracy in making general dose 
recommendations.5 
Single- vs. multiple-strain vs. multi-species products
The value of using a single-strain probiotic over a combination 
of probiotic strains or species is a topic of ongoing debate. 
Microorganisms may behave differently when administered in 
combinations, compared to in isolation. The use of combinations or 
cocktails concerns some investigators because attempts to classify 
the mechanism of action are then difficult to define.13 Within a product 
containing eight to 20 strains or even more, it may be fair to say that 
a few dominant strains will exert a greater effect, or discount the 
effects of others. Uncertainty exists as to whether the correct strain 
will be effective at the right time, and in the correct location. Each 
strain within a probiotic cocktail has been selected for a specific 
characteristic, such as the induction of a certain immune parameter. 
However, the same strain may have another immune modulating 
parameter that is not desired in the concerned application. These 
disadvantages do not mean that cocktails are undesirable, the 
so-called multistrain (containing more strains of the same genera, 
e.g. several Lactobacillus spp.) and multi-species (containing strains 
of different genera, e.g. lactobacilli, bifidobacteria, streptococci) may 
be more advantageous over mono-strain probiotics, particularly in 
people who are interested in probiotics to keep them healthy, and 
not aid management of a specific health concern. 
Probiotic preparations can be found in the form of powders, tablets, 
capsules, pastes, sprays or fermented foods, such as yoghurts, 
buttermilk, sour poi (a starchy paste made from the corm of taro 
plants) and miso (fermented soybean paste). The method of delivery, 
e.g. yoghurt vs. milk, may have an impact on the viability of the 
bacterial colonies. The probiotic product needs to have a good taste 
and smell, and an acceptable shelf-life.30 
Storage
Environmental conditions, such as moisture, oxygen, acid and 
heat, affect susceptible probiotic strains in different ways. Micro-
encapsulation or coating technologies (e.g. enteric coating) have 
been developed by manufacturers to ensure that a live probiotic, 
in the correct quantities, is delivered on ingestion. However, once 
a probiotic package is opened, these barriers are compromised. 
Generally microbes survive better at lower temperatures, but 
properly stabilised non-refrigerated products can retain potency at 
room temperature. Refrigerated products are also not necessarily 
of a better quality than non-refrigerated probiotics. Products 
need to be chosen from reputable companies that are labelled to 
reflect viability “through the end of shelf-life” and not “at time of 
manufacture”. Some products contain dried probiotics, and if these 
bacteria have been dried and stabilised properly, they remain alive, 
Review: Probiotics, with special emphasis on their role in the management of irritable bowel syndrome
66
Review: Probiotics, with special emphasis on their role in the management of irritable bowel syndrome
2011;24(2)S Afr J Clin Nutr
although dormant, and start to grow again after they reach the moist 
environment inside the body.5 By definition, the term “probiotic” 
can never be used to describe products comprising dead bacteria 
primarily, even though in some cases, dead bacteria or bacterial 
cell products have been shown to have physiological effects.44 For 
example, the administration of heat-killed Enterococcus faecalis 
to healthy dogs increased neutrophil phagocytes. These dead cells 
exert an anti-inflammatory response in the gastrointestinal tract. 
The variable amounts of dead cells found in probiotic products 
might contribute to the variation in response that is often seen with 
probiotic cultures.44
Adverse effects and safety issues
Although probiotics are generally considered to be safe, some 
research has revealed that probiotics may be inappropriate in 
specific populations. Probiotics have the potential to result in 
bacterial translocation across the gastrointestinal mucosa, and to 
transfer antibiotic resistance to other microorganisms. For these and 
other reasons, some adverse events have been linked to the use of 
probiotics in certain clinical settings. 
Patients receiving nutritional support have been studied extensively 
with regard to the use of probiotics in various scenarios, e.g. 
antibiotic-associated diarrhoea and Clostridium difficile-associated 
diarrhoea. Conditions where gastric pH is increased through 
medications, or where the stomach is bypassed, i.e. jejunal feeding, 
result in the increased survival of probiotics in the small bowel. 
Patients with a central venous catheter (CVC) are also a known risk 
category.
In one study, the efficacy of a multi-species probiotic was tested in 
patients with severe pancreatitis in an ICU setting. A significantly 
increased risk of death was reported in the group receiving the 
probiotic. The patients who died had evidence of necrotising 
jejunitis. In this study, a multi-species probiotic of various strains, 
previously not tested, was administered nasojejunally.45 This finding 
raised the possibility of an impaired splanchnic circulation that was 
further compromised by direct delivery of a high concentration of 
microorganisms into the proximal intestine. To date, this is the only 
study to associate probiotic use with increased risk of death in a 
clinical setting. However, Oláh et al did show that early nasojejunal 
feeding with a symbiotic preparation may prevent organ dysfunction 
in the late phase of severe acute pancreatitis, highlighting once 
again how much research still needs to be carried out in this area.46
A recent systematic review evaluated the safety of probiotic 
administration to patients receiving nutritional support (either 
enteral or parenteral nutrition).47 Bacteraemia (n = 5), fungaemia (n 
= 27) and endocarditis (n = 2) were reported, and the causative 
strains were Lactobacillus rhamnosus GG and Saccharomyces 
boulardii. The risk factors identified for these adverse events were 
patients receiving antibiotics with a CVC in situ, those at increased 
risk of bacterial translocation (i.e. with colitis or sepsis), and those 
with immune suppression [sepsis, human immunodeficiency virus 
(HIV) and necrotising enterocolitis]. It is argued that the two strains 
identified are the most commonly used in an ICU setting, and thus 
the reason for being cited. Similarly, the identified risk factors are 
general factors that are prevalent in most ICU patients, i.e. patients 
with a CVC and those receiving antibiotics. This systematic review 
evaluated studies published between 1996-2009, and only identified 
32 cases of adverse events out of a total of 4 131 patients receiving 
probiotics. 
As a result of the reported side-effects, the recommendations for the 
use of probiotics in various clinical settings are unclear. According 
to some, caution must be exercised when prescribing probiotics in 
newborns, immunocompromised patients, patients with pancreatitis, 
those with short-bowel syndrome, with a CVC in situ, and those 
with severe underlying illness.4 Others propose classifying the 
risk factors responsible for probiotic sepsis into major and minor 
categories. A major risk factor includes immunocompromised 
patients. Minor risk factors include a CVC, jejunal administration 
of probiotics, impaired intestinal epithelial barrier function, cardiac 
vascular disease (Lactobacillus only), and administration of a broad-
spectrum antibiotic to which a probiotic is resistant.48 Finally, some 
advocate that it is not contraindicated to prescribe probiotics to 
patients receiving various forms of nutrition support, or those that 
are immunocompromised, provided that it is done under proper 
medical supervision and with good monitoring systems in place.31,47 
Irritable bowel syndrome
The definition of IBS, according to the Rome III criteria, is that of 
a chronic disorder characterised by abdominal pain or discomfort 
associated with disordered defecation, either C-IBS, D-IBS, or mixed 
and alternating symptoms of constipation and diarrhoea.49 The 
patient group is heterogeneous. It is estimated that IBS affects 3-25% 
of the general population.50 The prevalence of IBS in South Africa 
is unknown. However, the progressive Westernisation of diets and 
lifestyles of less privileged populations is likely to be associated with 
an increased incidence of bowel disease and IBS. IBS patients can 
account for up to 30-50% of gastroenterology clinic visits.50 Various 
factors have been linked to the pathophysiology of IBS. These include 
altered bowel motility, enhanced visceral sensitivity, neurotransmitter 
imbalances, low-grade inflammation of the gastrointestinal 
mucosa, altered microflora and increased proinflammatory 
cytokine secretion.40,51-53 Elevated levels of cytokines IL-6, 
IL-6R, IL-1β and TNF-α,54,55 and a lower IL-10/IL-12 ratio,56 have 
been reported in IBS patients vs. controls.  
There is no single curative treatment, and therapy is aimed 
at reducing the symptoms, often with very little success.50 
Pharmacological treatment comprises the use of bulking agents, 
antispasmodics, dopamine antagonists and antidepressants. The 
handful of therapeutic agents that were previously useful in the 
management of global IBS symptoms have either been removed, 
or limited, due to adverse side-effects.57 Current treatment aims at 
strengthening or improving gastrointestinal epithelial function, and 
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improving the host’s immune ability. This has led to numerous clinical 
trials investigating the therapeutic benefit of probiotics in IBS.
Clinical trials involving probiotics and irritable bowel 
syndrome
Many of the clinical trials on probiotics and IBS have important 
weaknesses in trial design, study execution and data analysis. 
These weaknesses include not using the intention-to-treat group for 
analysis, involving only a specific group (e.g. C-IBS), while others 
have included both C-IBS and D-IBS, not stipulating whether C-IBS 
or D-IBS patients are being used, and using a crossover design 
where the treatment may “wash over” into the non-treatment 
period. There is a wide variety in dosing regimens, species used, and 
clinical end-points in probiotic or IBS clinical trials. Guidelines have 
been developed for clinical trials involving functional gastrointestinal 
disorders (including IBS).58 Recently, there have been two systematic 
reviews40,59 and four meta-analyses, one with particular emphasis 
on S. boulardii.50,60-62 
Twenty-eight double-blind, placebo-controlled, randomised trials 
were identified for the purposes of this review. Only those trials 
where the strain of the probiotic was clearly identified were used, 
regardless of type, dose and duration of treatment. The probiotics 
varied from one to multiple strains, and no symbiotic preparations 
were included.63,64  In the clinical trials, there had to be clear primary 
end-points. Single-blinded studies,65,66 those not using a control,63 
and non-randomised trials67 were excluded. To date, there have 
been two clinical trials that have focused on children aged six to 
20 years68 and six to 16 years.69 However, in this review, only those 
Table II: Clinical trials with probiotic use in IBS
Author n Probiotic preparation Treatment 
duration 
Results
O’Sullivan and O’Morain70 (2000) 24 Lactobacillus casei GG 20 weeks No significant differences between the two groups.
Nobaek and Johansson71 (2000) 60 L. plantarum 299v = DSM 9843 4 weeks Reduction in flatulence and pain.
Niedzielin and Kordecki72 (2001) 40
 
L. plantarum 299v 4 weeks Pain resolution and improvement in aGSS.
Sen and Mullan73 (2002) 12 L. plantarum 299v 4 weeks No significant difference between the two groups.
Kim et al74 (2003) 25 VSL#3 
(Bifidobacterium longum, B. infantis, 
B. breve, L. acidophilus, 
L. plantarum, L. casei, 
L. bulgaricus, Streptococcus 
salivarius spp. thermophilus) 
8 weeks Improvement in abdominal bloating, but no significant 
difference between the two groups.
Kim et al75 (2005) 48
 
VSL#3 4-8 weeks Significant reduction in flatulence.
Saggioro76 (2004) 70 L. plantarum LP01 and B. breve 
BR03 or L. plantarum LP01 and L. 
acidophilus LA02 or placebo
4 weeks Significant decrease in GSS and abdominal pain with probiotic 
combinations, compared to placebo.
Kajander et al77 (2005) 103
 
L. rhamnosus GG, L. rhamnosus 
LC705, B. breve Bb99, 
Propionibacterium freudenreichii 
spp. shermanii JS 
6 months Significant reduction in GSS (abdominal pain, distension, 
flatulence, and borborygmi). 
Lyra et al78 (2010) 42 L. rhamnosus GG, L. rhamnosus 
LC705, B. breve Bb99, 
Propionibacterium freudenreichii 
spp. shermanii JS
6 months Significant decrease in stool Bifidobacteria spp. in probiotic 
group.




L. rhamnosus GG, L. rhamnosus 
LC705, B. animalis spp. lactis Bb12, 
P. freudenreichii spp. shermanii JS 
5 months Significant reduction in GSS. 
Niv et al80 (2005) 54 L. reuteri ATCC 55730 6 months No significant differences between groups. Trend towards 
improvement in constipation and flatulence in treatment group.
O’Mahony et al56 (2005) 80 L. salivarius UCC4331 or B. infantis 
35624
8 weeks B. infantis reduced GSS, while L. salivarius reduced abdominal 
pain and discomfort, bloating and straining.
Whorwell et al42 (2006) 362 B. infantis 35624 in three different 
doses
4 weeks With 108 CFU, significant improvement in abdominal pain, 
bloating, bowel movement satisfaction, straining, passage of 
gas and evacuation.
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studies involving adults are presented. This review covers the 
important clinical studies over the past ten years. An overview of 
studies carried out on the use of probiotics in IBS is given in Table II, 
in which the main benefits (if found) are given in the results column.
In the following discussion, the various strains are not discussed 
individually. Rather, focus is placed on the strains that have provided 
positive results when treating IBS.
L. plantarum 299v
There are three small studies in which a liquid form of L. plantarum 
299v was used in the treatment of IBS. Two studies showed some 
benefit over placebo. One showed improved flatulence,71 and 
the other a reduction in abdominal pain.72 The third trial showed 
no significant benefit, but it was underpowered.73 There were 
differences in enrolled populations, study designs, outcomes and 
statistical analyses in these three trials. Tolerability and adverse 
events were poorly recorded. These smaller trials, although showing 
promising results, have never been followed up with larger, multi-
centre clinical studies. 
L. reuteri ATCC 55730 
A single trial of 54 IBS participants using L. reuteri ATCC 55730 over a 
six-month period, showed an improved global symptom score (GSS) 
from baseline until the end of the trial in both groups. There was a 
large placebo effect, and therefore failure in showing benefit over the 
controls.80 The study group was small, and was further reduced due 
to non-compliance during the trial. Compliance and adverse events 
were well reported. 
L. salivarius UCC4331
A single study, carried out by O’Mahony et al, used L. salivarius 
UCC4331 as part of a three-arm study evaluating the efficacy 
of L. salivarius UCC4331 and B. infantis 35624 compared to 
placebo for the treatment of IBS.56 After a four-week run-in period, 
50 participants received either L. salivarius or placebo for eight 
Author n Probiotic preparation Treatment 
duration 
Results
Guyonnet et al81 (2007) 274 B. animalis DN-173 010, 
S. thermophilus,  L. bulgaricus
6 weeks Significant improvement in quality of life, bloating and stool 
frequency in constipated participants.
Drouault-Holowacz et al82 (2008) 116 B. longum LA101, L. acid LA102,
L. lactis LA103, S. thermophilus 
LA104
4 weeks No significant difference in GSS.
Agrawal et al83 (2008) 41 B. lactis DN-173 010 4 weeks Significant improvements in objectively measured abdominal 
girth, gastrointestinal transit time. Reduced symptoms.
Sinn et al84 (2008) 40 L. acidophilus SDC 2012, 2013 4 weeks Significant improvement in treatment group with abdominal 
pain, pain while straining to pass a stool, bowel habit 
satisfaction and sense of incomplete evacuation.
Enck et al85 (2008) 297 Escherichia coli DSM 17252, 
Enterococcus faecalis DSM 16440
8 weeks Significant reduction in GSS and pain.
Enck et al86 (2009) 298 E. coli DSM 17252 8 weeks Significant reduction in GSS and pain.
Dolin87 (2009) 61 Bacillus coagulans GBI-30, 6086 8 weeks Significant reduction in number of bowel movements in D-IBS 
participants.
Hun88 (2009) 44 Bacillus coagulans GBI-30, 6086 8 weeks Significant improvement from baseline abdominal pain and 
bloating to end-point scores.
Williams et al89 (2009) 52 L. acidophilus CUL60, CUL21, B. 
lactis CUL34, B. bifidum CUL20
8 weeks Significant improvement in GSS, quality of life, days with pain 
and bowel habit satisfaction.
Hong et al90 (2009) 70 B. bifidum BGN4, B. lactis AD011, L. 
acidophilus AD031, L. casei IBS041
8 weeks Significant reduction in abdominal pain.
Ligaarden et al91 (2010) 16 L. plantarum MF 1298 2 x 3 weeks Significantly higher symptomatic relief satisfaction while on 
placebo.
Simrén et al92 (2010) 74 L. paracasei ssp. paracasei F19, L. 
acidophilus La5, B. lactis Bb12
8 weeks Significant improvement in GSS in both groups.
Søndergaard et al93 (2011) 64 L. paracasei ssp. paracasei F19, L. 
acidophilus La5, B. lactis Bb12
8 weeks No significant improvement in abdominal pain.
Guglielmetti et al94 (2011) 122 B. bifidum MIMBb75 4 weeks Significant improvement in GSS and quality of life in probiotic 
group.
Choi et al95 (2011) 67 S. boulardii 4 weeks Significant improvement in quality of life, but not symptoms.
a = global symptom score
70
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weeks, followed by a four week washout period. At the end of the 
trial, a significant reduction in abdominal pain and discomfort was 
seen at weeks two and seven with L. salivarius UCC4331, but this 
effect was not sustained. This was a well-designed study, and limited 
only by a lack of statistical power.
B. infantis 35624
In the previously mentioned trial of O’Mahony et al,56 77 patients 
with IBS were randomly assigned B. infantis, L. salivarius or placebo. 
The B. infantis (not L. salivarius) was shown to reduce pain, bloating 
and bowel satisfaction scores. The benefit of B. infantis has been 
replicated in a large multicentred research trial in 362 female 
patients with IBS. Participants were randomised to receive either 
106, 108 or 1010 CFU/day, or placebo.42 The group taking 108 CFU/day 
scored significantly better than the placebo in all symptom groups, 
including global assessment of IBS relief as the primary end-point. 
The bacteria in the group taking 1010 CFU/day were found to be 
nonviable later, perhaps explaining the lack of efficacy.
B. animalis subsp. lactis 
(Sometimes commercially known as B. lactis DN-173 010) 
Several well-designed, large multicentred trials of the use of 
B. animalis subsp. lactis in IBS have failed to demonstrate benefit, 
again often in part as a result of a high placebo response.63,81 A French 
multicentre trial of B. animalis subsp. lactis in 274 patients with 
C-IBS in primary care, demonstrated symptomatic relief compared 
with baseline in its primary end-point, but not over placebo.81 
However, subgroup analysis of patients with fewer than three bowel 
motions a week (n = 19) at baseline showed a significant increase in 
stool frequency compared with controls (p-value < 0.001). In a single 
trial carried out by Agrawal et al,83 34 IBS patients were randomised 
to either receive fermented milk containing B. animalis subsp. 
lactis or placebo for a four-week period. Compared with the control 
product, the test product resulted in a significant change in maximal 
distension [median difference -39%, 95% CI (-78, –5; p-value = 
0.02]. An accelerated orocaecal [-1.2 hours (-2.3, 0); p-value = 
0.049], as well as colonic [-12.2 h (9-22.8, -1.6); p-value = 0.026] 
transit, was observed, and overall symptom severity [-0.5 (-1.0, 
-0.05): p-value = 0.032] also improved. The probiotic resulted in 
improvements in objectively measured abdominal girth (distension) 
and gastrointestinal transit, as well as reduced symptomatology.83
Escherichia coli DSM 17252
A primary-care-based, placebo-controlled trial86 was conducted 
in 298 patients with IBS, diagnosed by a primary care standard 
(not Rome criteria96) and was defined as “clinical remission” with 
complete resolution of IBS symptoms.97 In comparison with the 
placebo, the treatment arm was reported to have achieved complete 
remission in 18.4% vs. 4.6% (p-value < 0.0004) of the patients 
studied. In addition, a 50% decrease in abdominal pain scores was 
recorded (18.9% vs. 6.7% in the treatment and placebo groups, 
respectively (p-value = 0.001)). This trial was based on a much 
earlier trial of E. coli DSM 17252 in combination with Enterococcus 
faecalis (DSM 16440), originally published in 1993,98 and more 
recently reanalysed85 by redefining the clinical end-points to give 
a GSS in accordance with modern guidelines. This reanalysis 
showed a significantly better response rate, defined by a decrease 
of 50%, in the treatment arm than the placebo (68.5% vs. 37.8%; 
p-value < 0.001). Although both these arms failed to use Rome II96 
or the definitions of Manning et al99 as their inclusion criteria, they 
were otherwise large and well-designed trials. Data from primary 
care, rather than secondary care patients, are particularly useful, 
given that the majority of IBS patients are treated by primary care 
physicians.
The role of probiotics in gastrointestinal disease, and in particular 
IBS, has clearly not been determined adequately. Although questions 
exist on the dosage and viability of probiotic strains, lack of industry 
standardisation and potential safety issues (with specific regard 
to immunocompromised or seriously ill patients),100 substantial 
clinical evidence of the advantageous use of probiotics over a wide 
range of clinical conditions exists. As there is currently no curative 
treatment for IBS, the relief that probiotic usage may provide, no 
matter how small, may motivate patients and caregivers to utilise 
them. Continuing research will recognise and characterise existing 
strains, identify specific outcomes, determine optimal doses needed 
for certain results, and assess their stability through processing and 
digestion.56 The heterogeneity of IBS and very high placebo response 
(up to 50%) are problems that are associated with clinical trials. 
Inevitably, the low-quality design of the trials on IBS and probiotics 
has led to concluding statements such as: “Further studies are 
needed to determine whether the probiotic under study may offer 
clinical benefits for IBS”. 
Future studies should use Rome III guidelines for the appropriate 
design of functional gastrointestinal trials.101 These guidelines also 
include sample size calculation, which should be based on the 
expected behaviour of the primary outcome measure. A study must 
have sufficient power to detect the minimal clinically important 
difference.102 With these data, clinicians will be better able to guide 
patients to efficacious and safe probiotics. Probiotics may be a safe 
and effective solution, and are urgently needed in the treatment and 
management of IBS.  
Regulatory aspects of probiotics
Testing for the probiotic potential of various microorganisms 
commences at the preclinical level, and includes animal studies and 
evaluations of antibiotic resistance, safety and potential efficacy.103 
Many studies, both in animal and human clinical trials, report success 
in reducing the severity of diseases by the use of a certain probiotic 
strain, but not by the use of others for the same condition. The need 
for research to determine the underlying mechanisms of action of 
specific probiotics will help in determining which specific organism 
is most likely to benefit a specific disease condition.13 The specific 
bacterium should be defined by its genus and species, as well as its 
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strain level. This is not always adhered to in scientific publications.104
It is often incorrectly stated that probiotic products are unregulated. 
The US Food and Drug Administration has regulatory authority over 
probiotic products and regulates manufacturers’ responsibilities, 
including the labelling and safety of these products, whether in food, 
supplement or drug form.41 In South Africa, permissible statements 
regarding the health benefits of probiotics are included in the 
regulations governing labelling and advertising in the Foodstuffs, 
Cosmetics and Disinfectants Act, 1972 (Act No. 54 of 1972; www.
doh.gov.za). The South African guidelines and regulations need to be 
revised regularly to accommodate the results of ongoing scientific 
research in the field of probiotics.105 
Conclusion
Effective treatment of IBS is often masked by its various groupings 
(C-IBS, D-IBS or post-infectious IBS) and their response to a 
particular treatment. Much of the published data do not differentiate 
between the groupings or subgroups, making interpretation of 
reported results difficult. Effective treatment outcomes are further 
compounded by variations in indigenous microbiota, as observed 
in stool microbiota, and possible varying aetiology among patients. 
Specific probiotic strains may work better in patients with either 
C-IBS or D-IBS. The strains that have shown good results to date 
include bifidobacteria, lactobacilli, E. coli and mixtures of different 
bacterial strains. Both B. infantis 35624 and L. plantarum 299v have 
demonstrated promising initial results in IBS clinical trials as single 
composites, but as yet, they have not been studied in combination, 
and a combination or “cocktail” probiotic of these two strains does 
not exist. It would be beneficial to assess the effects of these two 
probiotic strains in the treatment of IBS symptoms. 
It is important that probiotic clinical findings are not extrapolated 
to other clinical settings. Knowledge of the various properties 
of probiotics will prove to be fundamental in improving patient 
management. To date, it has been difficult to demonstrate a specific 
mechanism of action via the intestinal immune system, the enteric 
nervous system, or otherwise.106 This knowledge would help to 
answer the question of whether we have the relevant probiotics to 
manage IBS.
Probiotics and their benefits are an area of intensive research in 
various domains. Functional foods, with complex modes of action, 
may provide an alternative to the pharmacological approach in 
patients who require lifetime probiotic treatment, and/or who 
suffer from serious side-effects or drug resistance development. 
It is important to balance the potential benefits against the harms. 
Probiotics need to be carefully selected in a strain-specific manner. 
Thoroughly assessed, probiotic strains will possibly present as 
alternatives to individuals for whom traditional medical therapies 
have been unsuccessful, and perhaps, in the future, even serve as a 
first choice of therapy for some patients. 
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